Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644817 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1THRBCA1 | |
| SCHEMBL3812561 | 0.87 | LMNA (0.43) | ALDH1A1KMT2AMEN1THRBHTT | |
| SCHEMBL27586588 | 0.86 | KMT2A (0.50) | ALDH1A1KMT2AMEN1THRBCA1 | |
| SCHEMBL3815831 | 0.85 | MAPT (0.44) | ALDH1A1KMT2AMEN1THRBHTT | |
| SCHEMBL3815024 | 0.85 | MAPT (0.43) | ALDH1A1THRBLMNA | |
| SCHEMBL3817908 | 0.83 | KMT2A (0.60) | ALDH1A1KMT2AMEN1THRBCA1 | |
| SCHEMBL3382445 | 0.82 | THRB (0.57) | ALDH1A1KMT2AMEN1THRBCA1 | |
| SCHEMBL3817867 | 0.82 | PARP14 (0.48) | KMT2AMEN1THRBMMP2HTT | |
| SCHEMBL6109028 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1THRBCA1 | |
| SCHEMBL6109023 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1THRBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| CN-100351243-C | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4- (2-nucleobase acetyl) -piperazin-2-one | PANAGENE INC (KR) | 2007-11-28 | — | — | CN | disclosed |
| US-7022851-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-04-04 | — | — | US | disclosed |
| CN-1642923-A | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones | PANAGENE INC (KR) | 2005-07-20 | — | — | CN | disclosed |
| EP-1470114-A4 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2005-05-11 | — | — | EP | disclosed |
| EP-1470114-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | Panagene, Inc. (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030195332-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003062212-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195332-A1 | PNA monomer and precursor | RNGTT, NGLY1, NCL | ALDH1A1 3614/4885KMT2A 4121/4885MEN1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.